These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2009 related items for PubMed ID: 23322134

  • 21. New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
    Bhimani AA, Hong M.
    Rev Recent Clin Trials; 2013 Jun; 8(2):78-85. PubMed ID: 23859143
    [Abstract] [Full Text] [Related]

  • 22. Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
    Amin A, Stokes M, Makenbaeva D, Wiederkehr D, Wu N, Lawrence JH.
    J Med Econ; 2014 Nov; 17(11):771-81. PubMed ID: 25133458
    [Abstract] [Full Text] [Related]

  • 23. Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
    Lenchus JD.
    Hosp Pract (1995); 2013 Feb; 41(1):49-60. PubMed ID: 23466967
    [Abstract] [Full Text] [Related]

  • 24. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, Wells GA.
    Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
    [Abstract] [Full Text] [Related]

  • 25. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
    Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.
    Am J Cardiol; 2012 Aug 01; 110(3):453-60. PubMed ID: 22537354
    [Abstract] [Full Text] [Related]

  • 26. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
    Albert NM.
    Heart Lung; 2014 Aug 01; 43(1):48-59. PubMed ID: 24373340
    [Abstract] [Full Text] [Related]

  • 27. Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran.
    Prescrire Int; 2012 Nov 01; 21(132):257-60. PubMed ID: 23210252
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB.
    BMJ; 2017 Feb 10; 356():j510. PubMed ID: 28188243
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Novel oral anticoagulants: a review of new agents.
    Wanat MA.
    Postgrad Med; 2013 Jul 10; 125(4):103-14. PubMed ID: 23933899
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
    Morales-Vidal S, Schneck MJ, Flaster M, Biller J.
    Expert Rev Neurother; 2012 Feb 10; 12(2):179-89; quiz 190. PubMed ID: 22288673
    [Abstract] [Full Text] [Related]

  • 34. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A, Lane DA, Torp-Pedersen C, Lip GY.
    Thromb Haemost; 2012 Mar 10; 107(3):584-9. PubMed ID: 22186961
    [Abstract] [Full Text] [Related]

  • 35. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
    Prescrire Int; 2012 Feb 10; 21(124):33-6. PubMed ID: 22413715
    [Abstract] [Full Text] [Related]

  • 36. {blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
    Drug Ther Bull; 2014 Jan 10; 52(1):6-9. PubMed ID: 24401533
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F, Larsen TB, Rasmussen LH, Lip GY.
    Thromb Haemost; 2014 May 05; 111(5):981-8. PubMed ID: 24577485
    [Abstract] [Full Text] [Related]

  • 39. Overview of the new oral anticoagulants: opportunities and challenges.
    Yeh CH, Hogg K, Weitz JI.
    Arterioscler Thromb Vasc Biol; 2015 May 05; 35(5):1056-65. PubMed ID: 25792448
    [Abstract] [Full Text] [Related]

  • 40. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
    Harrington AR, Armstrong EP, Nolan PE, Malone DC.
    Stroke; 2013 Jun 05; 44(6):1676-81. PubMed ID: 23549134
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 101.